Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
seekingalpha.com
finance
2022-10-16 15:30:00

Solskin/DigitalVision via Getty Images Deals and Financings Jiangxi Jemincare, a China pharma formed in 1999, out-licensed global rights for its androgen receptor degrader to Roche (OTCQX:RHHBY, OTCQX:RHHBF) in a $650 million agreement (see story). JMKX002992 is being developed to treat prostate cancer patients who have developed resistance to current therapies. The oral small-molecule candidate, which was developed in Shanghai Jemincare's 500-scientist R&D center, is currently in preclinical testing.
